MC

481.7

+1.31%↑

BNP

78.97

+0.71%↑

DB1.DE

252.1

-0.67%↓

NDA.FI

12.84

+0.55%↑

DIM

179.1

-0.03%↓

MC

481.7

+1.31%↑

BNP

78.97

+0.71%↑

DB1.DE

252.1

-0.67%↓

NDA.FI

12.84

+0.55%↑

DIM

179.1

-0.03%↓

MC

481.7

+1.31%↑

BNP

78.97

+0.71%↑

DB1.DE

252.1

-0.67%↓

NDA.FI

12.84

+0.55%↑

DIM

179.1

-0.03%↓

MC

481.7

+1.31%↑

BNP

78.97

+0.71%↑

DB1.DE

252.1

-0.67%↓

NDA.FI

12.84

+0.55%↑

DIM

179.1

-0.03%↓

MC

481.7

+1.31%↑

BNP

78.97

+0.71%↑

DB1.DE

252.1

-0.67%↓

NDA.FI

12.84

+0.55%↑

DIM

179.1

-0.03%↓

Search

Gimv NV

Slēgts

SektorsFinanšu

41.95 -1.29

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

41.7

Max

42.45

Galvenie mērījumi

By Trading Economics

Ienākumi

145M

Pārdošana

-74M

114M

P/E

Sektora vidējais

5.663

25.916

EPS

2.45

Dividenžu ienesīgums

6.05

Peļņas marža

722.337

Darbinieki

94

EBITDA

-70M

76M

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

6.05%

3.70%

Nākamie ieņēmumi

2025. g. 30. sept.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-52M

1.6B

Iepriekšējā atvēršanas cena

43.24

Iepriekšējā slēgšanas cena

41.95

Ziņu noskaņojums

By Acuity

34%

66%

118 / 536 Rangs Finance

Gimv NV Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 29. jūl. 23:57 UTC

Iegādes, apvienošanās, pārņemšana

EQT: To Spend Y407.82B for Tender Offer

2025. g. 29. jūl. 23:56 UTC

Iegādes, apvienošanās, pārņemšana

EQT: Tender Offer Price Is Y5,700 a Share

2025. g. 29. jūl. 23:54 UTC

Iegādes, apvienošanās, pārņemšana

EQT To Start Tender Offer for Fujitec

2025. g. 29. jūl. 23:50 UTC

Tirgus saruna

Nikkei May Fall Amid Uncertainty Over Earnings, Domestic Politics -- Market Talk

2025. g. 29. jūl. 23:36 UTC

Tirgus saruna

Gold Steady Ahead of FOMC Decision -- Market Talk

2025. g. 29. jūl. 22:57 UTC

Tirgus saruna

Perseus May Step Up Capital Management at FY 2025 Result -- Market Talk

2025. g. 29. jūl. 22:50 UTC

Tirgus saruna

Mondelez Warns of Price Increases in North America -- Market Talk

2025. g. 29. jūl. 22:44 UTC

Iegādes, apvienošanās, pārņemšana

St Barbara: Potential Divestment of Nova Scotia Ops to be Weighed in 1Q FY26

2025. g. 29. jūl. 22:41 UTC

Iegādes, apvienošanās, pārņemšana

St Barbara FY25 All-in Sustaining Cost A$4,582/Oz

2025. g. 29. jūl. 22:41 UTC

Iegādes, apvienošanās, pārņemšana

St Barbara 4Q All-in Sustaining Cost A$4,613/Oz

2025. g. 29. jūl. 22:35 UTC

Peļņas

IGO Maintains Nova Life of Mine Production Guidance

2025. g. 29. jūl. 22:35 UTC

Peļņas

IGO Expects FY 2026 Greenbushes Output of 1.50 Million-1.65 Million Tons

2025. g. 29. jūl. 22:35 UTC

Peļņas

IGO Expects FY 2026 Greenbushes Cash Costs of A$310-A$360/Ton

2025. g. 29. jūl. 22:34 UTC

Peļņas

IGO Expects Train 1 of Kwinana Refinery to Be Fully Impaired

2025. g. 29. jūl. 22:34 UTC

Peļņas

IGO Expects to Impair Kwinana Refinery Assets by A$70 Million-A$90 Million

2025. g. 29. jūl. 22:34 UTC

Tirgus saruna
Peļņas

Mondelez Snack Demand Holding Up Better in Europe Than U.S. -- Market Talk

2025. g. 29. jūl. 22:33 UTC

Peļņas

IGO Had A$279.7 Million of Cash at End-June

2025. g. 29. jūl. 22:33 UTC

Peļņas

IGO 4Q Underlying Free Cash A$2.4 Million

2025. g. 29. jūl. 22:33 UTC

Peļņas

IGO FY Sales Revenue A$512.5 Million

2025. g. 29. jūl. 22:33 UTC

Peļņas

IGO 4Q Sales Revenue A$126.9 Million, Up 15% on 3Q

2025. g. 29. jūl. 22:32 UTC

Peļņas

IGO FY Nickel Production 17,173 Tons

2025. g. 29. jūl. 22:32 UTC

Peļņas

IGO 4Q Nickel Production 5,107 Tons, Up 22% on 3Q

2025. g. 29. jūl. 22:32 UTC

Peļņas

IGO 4Q Lithium Hydroxide Production 2,126 Tons, Up 36% on 3Q

2025. g. 29. jūl. 22:31 UTC

Tirgus saruna
Peļņas

Global Equities Roundup: Market Talk

2025. g. 29. jūl. 22:31 UTC

Tirgus saruna
Peļņas

Mondelez Sees Consumers Trading Down, Buying in Bulk -- Market Talk

2025. g. 29. jūl. 22:31 UTC

Peļņas

IGO 4Q Spodumene Cash Cost A$366/Ton, Up 7% on 3Q

2025. g. 29. jūl. 22:31 UTC

Peļņas

IGO FY Spodumene Production 1.48 Million Tons

2025. g. 29. jūl. 22:30 UTC

Peļņas

IGO 4Q Spodumene Production 340,000 Tons, Flat on 3Q

2025. g. 29. jūl. 22:30 UTC

Peļņas

IGO 4Q Underlying Ebitda A$62 Million

2025. g. 29. jūl. 22:22 UTC

Peļņas

Starbucks Abandons Mobile Order, Pickup-Only Stores -- WSJ

Salīdzinājums

Cenas izmaiņa

Gimv NV Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

0

Pirkt

0

Turēt

0

Pārdot

Noskaņojums

By Acuity

118 / 536 Rangs Finanšu

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Vidējais

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Gimv NV

Gimv NV is a private equity and venture capital firm specializing in direct and fund of funds investments. For direct investments, the firm specializes in buyouts, growth capital, middle market, debt, shareholder loans, seed, startups, early to mid-stage, late venture, public to private transactions, small and medium sized enterprises, later stage, mature, replacement capital, bridge financing, and recapitalization. Within fund of funds, it seeks to invest in venture capital and private equity funds. It seeks to invest in high performance growth companies that respond to that can speed up their internal growth through acquisitions. The firm typically invests in consumer, connected consumer, fintech; health and care; smart industries; and sustainable cities. Within consumer, it seeks to provide growth capital to emerging leaders. Within health and care platform, the firm seeks to invest in companies that can grow either organically or through a buy and build strategy. Within consumer, it focuses on consumer goods, food and beverage, healthy food, sport, convenience food, personal luxury, career, home & deco, baby & kids, pet products, retail, consumer services, media and content, travel and leisure, education, digital economy and online sectors. Within health and care sector, it focuses on life sciences, medtech, and health and care services. The firm focuses on biotech/biopharma comprising drugs, platform technologies, vaccines and diagnostic tests, preclinical, early clinical, and late clinical, medtech such as medical devices, consumables, IT and small equipment, and health and care services-based companies. It also seeks to be an active shareholder, preferably lead or co-lead in its investments. Within smart industries, it focuses on equipment, services and tools for resource efficient development and production, automotive and aerospace, both optimizing of the existing and development of new means of transport, software and services harnessing the flexibility of the cloud, smart data management and advanced c